Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy
Version of Record online: 20 MAY 2013
© 2013 The Authors. Psychiatry and Clinical Neurosciences © 2013 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 67, Issue 4, pages 219–227, May 2013
How to Cite
Woo, Y. S., Bahk, W.-M., Jeong, J.-H., Lee, S.-H., Sung, H.-M., Pae, C.-U., Koo, B.-H. and Kim, W. (2013), Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy. Psychiatry and Clinical Neurosciences, 67: 219–227. doi: 10.1111/pcn.12042
- Issue online: 20 MAY 2013
- Version of Record online: 20 MAY 2013
- Manuscript Accepted: 30 MAY 2012
- Manuscript Revised: 26 APR 2012
- Manuscript Received: 27 JAN 2012
- major depressive disorder;
- treatment resistance
The goal of this study was to assess the efficacy and tolerability of tianeptine in combination with selective serotonin re-uptake inhibitor (SSRI) in partial responders or non-responders to SSRI monotherapy.
In this prospective, open-label, 6-week study, 150 patients with major depressive disorder who had previously not responded or partially responded to SSRI monotherapy were recruited. Tianeptine was given in combination with an SSRI for 6 weeks.
Significant improvements were observed in the mean scores of the Hamilton Depression Rating Scale (HDRS), Montgomery–Åsberg Depression Rating Scale (MADRS), and Clinical Global Impression–Severity (CGI-S). The change in the mean HDRS, MADRS, and CGI-S scores was significant from week 1. The response rates were 64.7% (HDRS) and 68.7% (MADRS), and the remission rates were 34.0% (HDRS) and 42.0% (MADRS) at week 6. Thirty-six patients (24.0%) reported adverse events that were determined by the investigator to be related to one of the study drugs. The tianeptine and SSRI combination was generally well-tolerated.
A combination strategy with tianeptine may be an effective and well-tolerated tool for patients who have failed to adequately respond to SSRI monotherapy.